CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vyne Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vyne Pharmaceuticals Ltd
7 Golda Meir Street, 3rd floor
Phone: +972 89316233p:+972 89316233 NESS-ZIONA, 7403650  Israel Fax: +972 89474356f:+972 89474356
This company was Merged or Acquired on 12/16/2020.
This company ceased filing statements with the SEC on 3/20/2020.
This is a Subsidiary, click here for the Parent Company
Business Summary
Vyne Pharmaceuticals Ltd, formerly known as Foamix Pharmaceuticals Ltd., is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its lead product candidate, FMX103, is Foamix’s investigational proprietary 1.5% minocycline foam formulation being developed for moderate-to-severe papulopustular rosacea in adults.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201912/31/2019YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products

Business Names
Business Name
Foamix Pharmaceutical Inc.
FOMX

General Information
Number of Employees: 81 (As of 2/1/2019)
Outstanding Shares: 61,581,972 (As of 1/6/2020)
Shareholders: 15
Stock Exchange: NASD
Federal Tax Id: 513368811
Fax Number: +972 89474356


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023